USANA's Q3 Loss Narrows, Sales Decline 4%; FY26 Outlook Lowered
USANA Health Sciences (USNA) reported a narrower Q3 loss of $5.56M, but sales declined 4% to $205.88M. The company lowered FY26 outlook, expecting $900M in sales and a $16M loss. Hiya Health saw subscriber growth, while Rise Wellness sales fell 45%. Shares dropped 12.58% in pre-market trading.
How this was made
The 30-second read
Why it matters
The guidance downgrade is likely to outweigh the modest loss improvement, prompting short‑term downside.
Market read
Earnings and guidance update for a mid‑cap health‑wellness company; potential sell pressure.
What to watch
Hiya subscriber growth and Core Nutritional margin improvement may support longer‑term upside.
Background
USANA Health Sciences released its Q3 FY26 results, narrowing loss but lowering FY26 guidance.
Ticker impact
USANA reported Q3 loss narrowing and cut FY26 sales, adjusted EBITDA and earnings guidance.
likely pressure as market prices in the lower FY26 outlook
Guidance reductions typically trigger sell pressure even when quarterly loss improves.
Market effects
Nutraceutical sector may see broader scrutiny as USANA lowers outlook.
U.S. health‑supplement stocks could face modest downside.
Limited to US‑listed health‑wellness companies.
Counterpoint
Loss narrowing could signal operational improvements that outweigh guidance cuts.
Key entities
- companyUSANA Health Sciences, Inc.
U.S. health‑supplement and wellness products provider.
